Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601754 | 0.90 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTNPSR1NQO1 | |
| SCHEMBL2601755 | 0.90 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTNPSR1NQO1 | |
| SCHEMBL2605586 | 0.86 | ALDH1A1 (0.44) | ALDH1A1LMNAHTTNPSR1SMN1; SMN2 | |
| SCHEMBL2601749 | 0.82 | ALDH1A1 (0.47) | ALDH1A1LMNAHTTNPSR1SMN1; SMN2 | |
| SCHEMBL2601747 | 0.81 | RAD52 (0.42) | ALDH1A1LMNAHTTNPSR1KMT2A | |
| SCHEMBL13017868 | 0.81 | LMNA (0.47) | ALDH1A1LMNAHTTNPSR1NQO1 | |
| SCHEMBL2129981 | 0.80 | SLC6A5 (0.38) | ALDH1A1LMNAHTTNPSR1NQO1 | |
| SCHEMBL2130106 | 0.78 | ALDH1A1 (0.36) | ALDH1A1LMNAHTTNPSR1HPGD | |
| SCHEMBL1726191 | 0.77 | TDP1 (0.37) | ALDH1A1LMNAHTTNPSR1HPGD | |
| SCHEMBL2601750 | 0.77 | ALDH1A1 (0.48) | ALDH1A1LMNAHTTNPSR1NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2403856-B1 | METHYLENEDIOXYBENZO [I]PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | UNIV RUTGERS (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| WO-2010102219-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | TOP2B, TOP1, TOP2A | ALDH1A1 1190/4885LMNA 1016/4885HTT 1894/4885 |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | ALDH1A1 1190/4885LMNA 1016/4885HTT 1894/4885 |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | ALDH1A1 1190/4885LMNA 1016/4885HTT 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.